Previous Article | Next Article ![]()
Journal of Clinical Microbiology, October 2001, p. 3757-3759, Vol. 39, No. 10
International Centre for Diarrhoeal Diseases
Research, Bangladesh, Dhaka-1000, Bangladesh,1
and Department of Molecular Biology, SBL Vaccin AB,
S-105 21 Stockholm, Sweden2
Received 19 April 2001/Returned for modification 26 June
2001/Accepted 7 August 2001
Of 469 recently isolated Shigella flexneri strains, 452 agglutinated with Shigella flexneri-specific monoclonal
antibodies. Of these, 396 could be assigned to 10 of the currently
recognized 15 serotypes, with S. flexneri 2b dominating
(23.2%). Of the 56 untypeable strains which showed invasive
properties, 17 were serologically atypical and the remaining 39 belonged to a new serotype.
Shigellosis is one of the major
diarrheal diseases in Bangladesh and several other developing countries
and is caused by any one of the four species or groups of
Shigella, namely, S. dysenteriae, S. flexneri, S. boydii, and S. sonnei. Each serogroup contains multiple
serotypes, and at least 47 serotypes are currently recognized based on
their biochemical and/or lipopolysaccharide characteristics. Based on
the structure of the O antigen, a component of the lipopolysaccharide present on the outer membrane of the cell (16), 15 serotypes of S. flexneri are currently recognized. Since
S. flexneri serotype 2a was found to be the major endemic
serotype in developing countries, the currently available candidate
vaccine is directed against S. flexneri 2a
(12). It is important to determine the prevalence of
various serotypes of S. flexneri in different communities
worldwide and to monitor the changes over time.
From 1 January 1997 to 30 June 2000, 469 clinical isolates of S. flexneri were isolated from patients attending the Dhaka treatment
center operated by the International Centre for Diarrhoeal Diseases
Research in Bangladesh. Shigella strains were isolated and
identified in the Clinical Microbiology Laboratory following standard
microbiological and biochemical methods (17). S. flexneri strains were serotyped using (i) a commercial antiserum
kit (Denka Saiken, Tokyo, Japan) and (ii) monoclonal antibody reagents
specific for all S. flexneri type and group factor antigens
(2, 3). Serological reactions were performed by the glass
slide agglutination test as described previously (6).
Plasmid DNA was prepared by the rapid alkaline lysis method of Kado and
Liu (8) and analyzed as described previously
(7). The Sereny test (9, 15) and
determination of the Congo red binding ability of S. flexneri (the results of both indicate invasive property) were
performed using procedures described elsewhere (13, 14).
During the study period, 469 strains were identified as S. flexneri based on agglutination with species-specific polyclonal rabbit antisera (Denka Saiken) and general biochemical tests. These
strains were further serotyped using the commercially available rabbit
antisera specific for all type and group factor antigens. Of the 469 strains, 359 could be serotyped with the commercial kit while 110 (23.4%) were untypeable. All of the 469 strains were then examined
using a panel of monoclonal antibodies against S. flexneri
(MASF) using the typing scheme shown in Table
1. All but 17 of the 469 strains
agglutinated strongly with MASF B (4), an S. flexneri species-specific monoclonal antibody (Table 1). When
retrospectively examined, the 17 strains that did not agglutinate with
MASF B were found to agglutinate with both S. flexneri and
S. boydii species-specific commercial polyclonal rabbit
antisera.
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.10.3757-3759.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Altering Trends in the Dominance of Shigella
flexneri Serotypes and Emergence of Serologically Atypical
S. flexneri Strains in Dhaka, Bangladesh
![]()
ABSTRACT
Top
Abstract
Text
References
![]()
TEXT
Top
Abstract
Text
References
TABLE 1.
Agglutination of S. flexneri isolates isolated
from January 1997 to June 2000 with MASF antibodies
Of the 452 strains that agglutinated with MASF B, 396 could be assigned to 10 of the currently recognized 15 serotypes of S. flexneri. The predominant S. flexneri serotypes determined using MASF were 2b (23.2%), 2a (15.5%), 3a (15.5%), 1b (15.3%), and 1c (8.2%), which together accounted for 77.7% of the S. flexneri strains examined in this study (Table 1). Of the remaining 56 strains of S. flexneri, which could not be definitively serotyped, 17 agglutinated with type antigen factor IV-2 but did not agglutinate with group factor Y-5 or 6, thereby excluding their characterization into serotype 4a or 4b. These 17 strains instead agglutinated with a new antigenic determinant, E1037 (IV-1) (Table 1). The remaining 39 of the untypeable strains agglutinated only with the provisional antigen, MASF IV-1, specific for a new antigenic determinant (E1037), but did not react with any type or group antigen-specific antisera tested.
Plasmid profile analysis of the 56 untypeable strains of S. flexneri along with the 37 S. flexneri 1c strains
showed that all the untypeable strains and 34 of the 1c strains
harbored the 140-MDa invasive plasmid (Table
2). All of the 56 untypeable S. flexneri strains had the ability to bind Congo red (Table 2), reflecting the invasive property of these strains. Twelve strains of
the 56 containing the 140-MDa plasmid and 3 strains of S. flexneri 1c which did not carry the 140-MDa plasmid were selected
at random and subjected to the Sereny test. The strains containing the
140-MDa plasmid were positive by the Sereny test, while the strains
without the 140-MDa plasmid were negative (Table 2).
|
The major observation in this study was that serotype 2b has now become the dominant serotype of S. flexneri prevalent in Dhaka. From a vaccine perspective, the shift in S. flexneri serotype dominance from 2a to 2b is not such a disconcerting event given the fact that S. flexneri serotypes, with the exception of serotype 6, have some degree of antigenic relatedness attributable to a common repeating tetrasaccharide unit (5). All previous studies on serotypes of S. flexneri in Bangladesh have shown 2a as the dominant serotype (1, 7, 10, 11), but this has now changed. In this study, E1037 was found in all of the type 4 strains and in a number of strains (designated as 4X) which reacted only with S. flexneri-specific MASF B (4). These appear to constitute a new serotype of S. flexneri with uncharacterized antigenic determinants. Serologically atypical strains displaying conflicting agglutination patterns have recently been reported among strains of S. flexneri isolated in rural Egypt, and this was attributed to limitations in the ability of available commercial antibody reagents to reliably detect the full diversity of serological variants of S. flexneri (6). We also observed that the commercially available antiserum kit could not type 23.4% of the S. flexneri strains, and 17 strains showed cross-reactions with S. boydii antisera. Another interesting trend was that the incidence of subserotype 1c is increasing, and the previously identified S. flexneri serotypes 3b, 3c, 4a, and 5b were not detected in this study while such serotypes as 1a, 5a, and X were disappearing. Recently El-Gendy et al. (6) reported that the antigenic determinant E1037 and MASF type antigen factor IV-2 are present in some strains of S. flexneri 1c isolated in rural Egypt. Overall, it appears that there is a changing profile in regard to the prevalence of various serotypes of S. flexneri.
The untypeable strains (those newly designated serotype 1c and the serologically atypically strains provisionally designated types 4 and 4X by use of monoclonal antibodies) were studied in order to determine whether these strains were invasive. With the exception of three, all the strains were found to harbor a large plasmid of approximately 140 MDa and had the ability to bind Congo red and produce keratoconjunctivitis in guinea pigs, attesting to their invasive properties. Three strains of serotype 1c did not harbor this plasmid and were avirulent.
| |
ACKNOWLEDGMENTS |
|---|
This study was funded by the United States Agency for International Development (USAID) under Cooperative Agreement No. HRN-A-00-96-90005-00 and ICDDRB, Centre for Health and Population Research, which is supported by countries and agencies which share its concern for the health problems of developing countries. Current donors providing unrestricted support include the following: the aid agencies of the governments of Australia, Bangladesh, Belgium, Canada, Japan, The Netherlands, Saudi Arabia, Sweden, Sri Lanka, Switzerland, the United Kingdom, and the United States; international organizations, including the United Nations Children's Fund.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Laboratory Sciences Division, International Centre for Diarrhoeal Diseases Research, Bangladesh, GPO Box-128, Dhaka-1000, Bangladesh. Phone: 880 2 8811751-60. Fax: 880 2 8812529 or 880 2 8823116. E-mail: kaisar{at}icddrb.org.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Carlin, N. I. A.,
M. Rahman,
D. A. Sack,
A. Zaman,
B. Kay, and A. A. Lindberg.
1989.
Use of monoclonal antibodies to type Shigella flexneri in Bangladesh.
J. Clin. Microbiol.
27:1163-1166 |
| 2. |
Carlin, N. I. A., and A. A. Lindberg.
1983.
Monoclonal antibodies specific for O-antigenic polysaccharides of Shigella flexneri: clones binding to II, II:3,4, and 7,8 epitopes.
J. Clin. Microbiol.
18:1183-1189 |
| 3. |
Carlin, N. I. A., and A. A. Lindberg.
1986.
Monoclonal antibodies specific for Shigella flexneri lipopolysaccharides: clones binding to the type antigens III and I:6,7,8, group antigen 6, and a core epitope.
Infect. Immun.
53:103-109 |
| 4. |
Carlin, N. I. A., and A. A. Lindberg.
1987.
Monoclonal antibodies specific for Shigella flexneri lipopolysaccharides: clones binding to type IV, V, and VI antigens, group 3,4 antigen, and an epitope common to all Shigella flexneri and Shigella dysenteriae type 1 strains.
Infect. Immun.
55:1412-1420 |
| 5. | Carlin, N. I. A., A. A. Lindberg, K. Bock, and D. R. Bundle. 1984. The Shigella flexneri O-antigenic polysaccharide chain. Nature of the natural repeating unit. Eur. J. Biochem. 139:189-194[Medline]. |
| 6. |
El-Gendy, A.,
N. El-Ghorab,
E. M. Lane,
R. A. Elyazeed,
N. I. A. Carlin,
M. M. Mitry,
B. A. Kay,
S. J. Savarino, and L. F. Peruski, Jr.
1999.
Identification of Shigella flexneri subserotype 1c in rural Egypt.
J. Clin. Microbiol.
37:873-874 |
| 7. | Haider, K., M. I. Huq, K. A. Talukder, and Q. S. Ahmad. 1989. Electropherotyping of plasmid deoxyribonucleic acid (DNA) of different serotypes of Shigella flexneri strains isolated in Bangladesh. Epidemiol. Infect. 102:421-428[Medline]. |
| 8. |
Kado, C. I., and S.-T. Liu.
1981.
Rapid procedure for detection and isolation of large and small plasmids.
J. Bacteriol.
145:1365-1373 |
| 9. | Mackel, D. C., L. F. Langley, and L. A. Venice. 1961. The use of the guinea-pig conjunctivae as an experimental model for the study of virulence of Shigella organisms. Am. J. Hyg. 73:219-223[Medline]. |
| 10. | Mutanda, L. N., A. K. M. G. Kibriya, M. N. Mansur, and M. I. Huq. 1980. Antibiotic-resistance and pattern of Shigella flexneri serotypes in Dacca. Bangladesh Med. J. 9:1-7. |
| 11. | Mutanda, L. N., A. K. M. G. Kibriya, and M. N. Mansur. 1981. Pattern of Shigella flexneri serotypes and drug-resistance in Dacca. Indian J. Med. Res. 73:8-12[Medline]. |
| 12. |
Noriega, F. R.,
G. Losonsky,
C. Lauderbaugh,
F. M. Liao,
M. S. Wang, and M. M. Levine.
1996.
Engineered guaBA virG Shigella flexneri 2a strain CVD 1205: construction, safety, immunogenicity, and potential efficacy as a mucosal vaccine.
Infect. Immun.
64:3055-3061[Abstract].
|
| 13. |
Sakai, T.,
C. Sasakawa,
S. Makino,
K. Kamata, and M. Yoshikawa.
1986.
Molecular cloning of a genetic determinant for Congo red binding ability which is essential for the virulence of Shigella flexneri.
Infect. Immun.
51:476-482 |
| 14. |
Sasakawa, C.,
K. Kamata,
T. Sakai,
S. Y. Murayama,
S. Makino, and M. Yoshikawa.
1986.
Molecular alteration of the 140-megadalton plasmid associated with loss of virulence and Congo red binding activity in Shigella flexneri.
Infect. Immun.
51:470-475 |
| 15. | Sereny, B. 1957. Experimental keratoconjunctivitis Shigellosa. Acta Microbiol. Acad. Sci. Hung. 2:293-296. |
| 16. |
Simmon, D. A., and E. Romanowska.
1987.
Structure and biology of Shigella flexneri O antigens.
J. Med. Microbiol.
23:289-302 |
| 17. | World Health Organization. 1987. Programme for control of diarrheal disease, p. 9-20. In Manual for laboratory investigation of acute enteric infections. World Health Organization, Geneva, Switzerland. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»